Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8023493 | 0.91 | PTGS2 (0.70) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL8023566 | 0.90 | PTGS2 (0.66) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL8033171 | 0.86 | PTGS2 (0.66) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL15070230 | 0.85 | PTGS2 (0.53) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL8032930 | 0.85 | PTGS2 (0.75) | PTGS2CA1CA2CA9CHRNA7 | |
| SCHEMBL8035264 | 0.84 | PTGS2 (0.65) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL8023934 | 0.83 | PTGS2 (0.73) | PTGS2CA1CA2CA9CHRNA7 | |
| SCHEMBL8023286 | 0.83 | PTGS2 (0.72) | PTGS2CA1CA2CA9CHRNA7 | |
| SCHEMBL8033030 | 0.83 | PTGS2 (0.72) | PTGS2CA1CA2CA9CHRNA7 | |
| SCHEMBL8039325 | 0.83 | PTGS2 (0.75) | PTGS2CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | PTGS2 3213/4885PTGS1 2564/4885CA1 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.